Related references
Note: Only part of the references are listed.EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
K. Almstedt et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population
Marcus Schmidt et al.
BREAST CANCER RESEARCH (2018)
Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer
A-S. Heimes et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Lyndsay N. Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
B cell-regulated immune responses in tumor models and cancer patients
Carlo Fremd et al.
ONCOIMMUNOLOGY (2013)
Immunomodulatory effects of anti-estrogenic drugs
Amitabha Ray et al.
ACTA PHARMACEUTICA (2012)
A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
Marcus Schmidt et al.
CLINICAL CANCER RESEARCH (2012)
Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer
Zonglin Chen et al.
PLOS ONE (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Breast Cancer 2 Gene expression profiling in breast cancer: classification, prognostication, and prediction
Jorge S. Reis-Filho et al.
LANCET (2011)
Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and -Negative Cancers
Giampaolo Bianchini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Effects of Tamoxifen on Immunity
S. Behjati et al.
CURRENT MEDICINAL CHEMISTRY (2009)
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Achim Rody et al.
BREAST CANCER RESEARCH (2009)
The humoral immune system has a key prognostic impact in node-negative breast cancer
Marcus Schmidt et al.
CANCER RESEARCH (2008)
Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2007)
The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation
G Nalbandian et al.
JOURNAL OF IMMUNOLOGY (2005)
Share Paper
